000131714 001__ 131714
000131714 005__ 20241125101154.0
000131714 0247_ $$2doi$$a10.1016/j.arbres.2023.09.009
000131714 0248_ $$2sideral$$a137093
000131714 037__ $$aART-2023-137093
000131714 041__ $$aeng
000131714 100__ $$aLacámara, Sergio
000131714 245__ $$aMTBVAC: A Tuberculosis Vaccine Candidate Advancing Towards Clinical Efficacy Trials in TB Prevention
000131714 260__ $$c2023
000131714 5060_ $$aAccess copy available to the general public$$fUnrestricted
000131714 5203_ $$aTuberculosis (TB) remains a major global health burden, causing more than 10 million new cases and 1.6 million deaths each year. Currently, the only approved TB vaccine in use in humans, is the one hundred years old vaccine, BCG, an attenuated vaccine derived from an isolate of Mycobacterium bovis that causes TB in cattle. BCG shows a variable efficacy in preventing pulmonary forms of the disease in humans, so new vaccines are needed to help stop TB transmission. Among the 15 diverse TB vaccine candidates in clinical trials, MTBVAC is the only one based on rational attenuation of a human clinical isolate of Mycobacterium tuberculosis, which contains the largest number of antigens of the TB vaccine candidates in the pipeline. MTBVAC was designed and constructed as a response to the need to confer a better TB protection in terms of pulmonary disease prevention in newborns, adolescents, and adults. This review aims to provide an overview of the preclinical and clinical development of MTBVAC to the present. We will focus on the clinical development of MTBVAC, and we will compare it with other TB vaccine candidates currently in Phase 3 efficacy trials.
000131714 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000131714 590__ $$a8.7$$b2023
000131714 592__ $$a0.464$$b2023
000131714 591__ $$aRESPIRATORY SYSTEM$$b9 / 101 = 0.089$$c2023$$dQ1$$eT1
000131714 593__ $$aPulmonary and Respiratory Medicine$$c2023$$dQ3
000131714 594__ $$a3.5$$b2023
000131714 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000131714 700__ $$0(orcid)0000-0003-2993-5478$$aMartin, Carlos$$uUniversidad de Zaragoza
000131714 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología
000131714 773__ $$g59, 12 (2023), 821-828$$pArch. bronconeumol.$$tArchivos de Bronconeumologia$$x0300-2896
000131714 8564_ $$s1834304$$uhttps://zaguan.unizar.es/record/131714/files/texto_completo.pdf$$yVersión publicada
000131714 8564_ $$s2823682$$uhttps://zaguan.unizar.es/record/131714/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000131714 909CO $$ooai:zaguan.unizar.es:131714$$particulos$$pdriver
000131714 951__ $$a2024-11-22-12:08:18
000131714 980__ $$aARTICLE